Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tri-Ad5 and N-803 in Lynch Syndrome
NCT05419011Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2023
- Primary completion
- Jul 2027
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Cytokines & Interferons
- Countries
- 2
01
Overview
A Phase 2 trial of Tri-Ad5, nogapendekin alfa in Lynch syndrome (LS), colorectal neoplasm, sponsored by National Cancer Institute. Started May 2023; status: active, not recruiting.
02
Drugs
Tri-Ad5nogapendekin alfa
03
Conditions
Lynch syndrome (LS)colorectal neoplasm
Beyond the preview
Go deeper on NCT05419011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05419011.